These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8289986)

  • 1. Oral calcium effectively reduces parathyroid hormone levels in hemodialysis patients: a randomized double-blind placebo-controlled study.
    Rudnicki M; Højsted J; Petersen LJ; Sørensen HA; Hyldstrup L; Transbøl I
    Nephron; 1993; 65(3):369-74. PubMed ID: 8289986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism.
    Goodman WG; Frazao JM; Goodkin DA; Turner SA; Liu W; Coburn JW
    Kidney Int; 2000 Jul; 58(1):436-45. PubMed ID: 10886592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
    Block GA; Martin KJ; de Francisco AL; Turner SA; Avram MM; Suranyi MG; Hercz G; Cunningham J; Abu-Alfa AK; Messa P; Coyne DW; Locatelli F; Cohen RM; Evenepoel P; Moe SM; Fournier A; Braun J; McCary LC; Zani VJ; Olson KA; Drüeke TB; Goodman WG
    N Engl J Med; 2004 Apr; 350(15):1516-25. PubMed ID: 15071126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
    Block GA; Bushinsky DA; Cheng S; Cunningham J; Dehmel B; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Moe SM; Patel UD; Silver J; Sun Y; Wang H; Chertow GM
    JAMA; 2017 Jan; 317(2):156-164. PubMed ID: 28097356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic follow-up of the intact parathormone levels in hemodialysis patients treated with Rocaltrol and calcium.
    Dimitrakov D; Koumtchev E; Dimitrova R; Stavrev P
    Folia Med (Plovdiv); 1998; 40(4):48-53. PubMed ID: 10371800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis.
    Greenbaum LA; Grenda R; Qiu P; Restaino I; Wojtak A; Paredes A; Benador N; Melnick JZ; Williams LA; Salusky IB
    Pediatr Nephrol; 2005 May; 20(5):622-30. PubMed ID: 15785941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of short daily hemodialysis in the control of hyperphosphatemia, secondary hyperparathyroidism and anemia.
    Jiang JL; Ren W; Li Y; Liu GY; Zhou CP; Su KL; Chen W; Wang K; Ni LJ; Hu Z
    Int Urol Nephrol; 2013 Dec; 45(6):1725-31. PubMed ID: 23591723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
    Lindberg JS; Culleton B; Wong G; Borah MF; Clark RV; Shapiro WB; Roger SD; Husserl FE; Klassen PS; Guo MD; Albizem MB; Coburn JW
    J Am Soc Nephrol; 2005 Mar; 16(3):800-7. PubMed ID: 15689407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.
    Lindberg JS; Moe SM; Goodman WG; Coburn JW; Sprague SM; Liu W; Blaisdell PW; Brenner RM; Turner SA; Martin KJ
    Kidney Int; 2003 Jan; 63(1):248-54. PubMed ID: 12472790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dietary calcium deprivation and secondary hyperparathyroidism in patients treated with chronic dialysis.
    Popovtzer MM; Michael UF; Johnson-Dial KS; Ronstadt C; Nelson D; Ogden DA
    Miner Electrolyte Metab; 1986; 12(5-6):298-302. PubMed ID: 3807827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Control of parathyroid function in patients with a short history of hemodialysis.
    Nishi H; Sato T; Kurihara T; Kurosawa T; Fukagawa M
    Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
    Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Lowering Dialysate Calcium Concentration on Mineral and Bone Disorders in Chronic Hemodialysis Patients: Conversion from 3.0 mEq/L to 2.75 mEq/L.
    Yamada S; Ueki K; Tokumoto M; Suehiro T; Kimura H; Taniguchi M; Fujimi S; Kitazono T; Tsuruya K
    Ther Apher Dial; 2016 Feb; 20(1):31-9. PubMed ID: 26482334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of pamidronate and calcitriol on the set point of the parathyroid gland in postmenopausal hemodialysis patients with secondary hyperparathyroidism.
    Huang CY; Zheng CM; Wu CC; Lo L; Lu KC; Chu P
    Nephron Clin Pract; 2012; 122(3-4):93-101. PubMed ID: 23635416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alphacalcidol oral pulses are effective in secondary hyperparathyroidism prior to dialysis.
    Koskimies O; Ala-Houhala M
    Clin Nephrol; 1996 Jul; 46(1):70-1. PubMed ID: 8832157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials.
    Block GA; Bushinsky DA; Cunningham J; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Mix TC; Moe SM; Patel UD; Silver J; Spiegel DM; Sterling L; Walsh L; Chertow GM
    JAMA; 2017 Jan; 317(2):146-155. PubMed ID: 28097355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-trending of parathyroid hormone and phosphate in patients receiving hemodialysis.
    Block G; Do TP; Collins AJ; Cooper KC; Bradbury BD
    Clin Nephrol; 2016 Mar; 85(3):142-51. PubMed ID: 26784912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of gastric acid suppression with pantoprazole on the efficacy of calcium carbonate as a phosphate binder in haemodialysis patients.
    Cervelli MJ; Shaman A; Meade A; Carroll R; McDonald SP
    Nephrology (Carlton); 2012 Jul; 17(5):458-65. PubMed ID: 22471559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.